Eisai Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EISAI INC, and when can generic versions of EISAI INC drugs launch?
EISAI INC has eleven approved drugs.
There are twelve US patents protecting EISAI INC drugs.
There are three hundred and ten patent family members on EISAI INC drugs in forty-two countries and thirty-nine supplementary protection certificates in eighteen countries.
Summary for Eisai Inc
| International Patents: | 310 |
| US Patents: | 12 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 11 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Eisai Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | 10,259,791 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | 8,268,848 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | RX | Yes | Yes | RE46965*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Eisai Inc | HEXALEN | altretamine | CAPSULE;ORAL | 019926-001 | Dec 26, 1990 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eisai Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 8,097,648 | ⤷ Try a Trial |
| Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | 7,727,548 | ⤷ Try a Trial |
| Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | 7,727,552 | ⤷ Try a Trial |
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-002 | Nov 14, 2008 | 7,750,028*PED | ⤷ Try a Trial |
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-001 | Nov 25, 1996 | 6,140,321 | ⤷ Try a Trial |
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 6,469,182 | ⤷ Try a Trial |
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-001 | Nov 14, 2008 | 7,750,028*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
| ➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
| ➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
| ➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
International Patents for Eisai Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Poland | 1698623 | ⤷ Try a Trial |
| China | 103550190 | ⤷ Try a Trial |
| Poland | 2522663 | ⤷ Try a Trial |
| South Korea | 20070086667 | ⤷ Try a Trial |
| European Patent Office | 3209298 | ⤷ Try a Trial |
| Russian Federation | 2013117464 | ⤷ Try a Trial |
| Japan | 2005272474 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eisai Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1087960 | C01087960/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: ERIBULIN; REGISTRATION NO/DATE: SWISSMEDIC 59489 20110513 |
| 1698623 | C20150042 00382 | Estonia | ⤷ Try a Trial | PRODUCT NAME: LENVATINIIB;REG NO/DATE: EU/1/15/1002 01.06.2015 |
| 0994863 | 91345 | Luxembourg | ⤷ Try a Trial | CERTIFICATE NAME: RUFINAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (INOVELON); FIRST REGISTRATION DATE: 20070116 |
| 1087960 | 132011901976051 | Italy | ⤷ Try a Trial | PRODUCT NAME: ERIBULINA(HALAVEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/678/001-002, 20110317 |
| 1087960 | C300493 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ERIBULIN, ALSMEDE FARMACEUTISCHE ZOUTEN ERVAN, IN HET BIJZONDER HET MESYLAAT; REGISTRATION NO/DATE: EU/1/11/678/001-002 20110317 |
| 1698623 | PA2015039,C1698623 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528 |
| 1415987 | 92858 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
